The US Food and Drug Administration has approved Juvisync (sitagliptin and simvastatin) from Merck & Co, the first combination drug for Type 2 diabetes and high cholesterol to be put on the market as a single tablet. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
